Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 2, 1999, Pages 201-206

  Buskin, Susan E ^a,b   Newcomer, Laura M ^a   Koutsky, Laura A ^a   Hooton, Thomas M ^a   Spach, David H ^a   Hopkins, Sharon G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

AIDS mortality; Bacterial infections; HIV infection; Pneumocystis carinii pneumonia; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033080881     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199902010-00014     Document Type: Article

References (22)

1. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995;123:933-6.
2. Meyer CN, Skinhoj P, Prag J. Bacteremia in HIV-positive and AIDS patients: incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment. Scand J Infect Dis 1994;26:635-42.
3. Rosen MJ. Pneumonia in patients with HIV infection. Med Clin North Am 1994;78:1067-79.
4. Burack JH, Hahn JA, Saint-Maurice D, Jacobson MA. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection. Implications for rational empiric antibiotic therapy. Arch Intern Med 1994;154:2589-96.
5. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR 1997;46(RR-12):1-46
6. Cohn DL. Bacterial pneumonia in the HIV-infected patient. Infect Dis Clin North Am 1991;5:485-507.
7. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992;327:1842-8.
8. Tabet SR, Krone MR, Hooton TM, Koutsky LA, Holmes KK. Bacterial infections in adult patients hospitalized with AIDS: case-control study of prophylactic efficacy of trimethoprim-sulfamethoxazole versus aerosolized pentamidine. Int J STD AIDS 1997;8:563-9
9. Edge MD, Rimland D. Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole. AIDS 1996; 10:1635-9.
10. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333:845-51
11. Podzamczer D, Salazar A, Jiménez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;122:755-61.
12. May T, Beuscart C, Reynes J, at al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. J Acquir Immune Defic Syndr 1994;7:457-62.
13. Schneider MM, Hoepelman AI, Eeftinck-Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992;327:1836-41.
14. Chaisson RE, Keruly J, Richman DD, Moore RD. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. Arch Intern Med 1992;152:2009-13.
15. Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.-JAMA 1995;273:1197-202.
16. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus in the United States. JAMA 1992;267:1798-1805.
17. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(Suppl 1S):1-15.
18. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19.
19. Centers for Disease Control and Prevention. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992;41(RR-4):1-11.
20. Caumes E. Value of desensitization for reintroducing trimethoprim-sulfamethoxazole in hypersensitive patients with HIV infection. Ann Med Interne Paris 1997;148:172-6.
21. Graham NM, Jacobson LP, Kuo V, Chmiel JS, Morgenstern H, Zucconi SL. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol 1994;47:1003-12.
22. Martin MA, Cox PH, Beck K, Styer CM, Beall GN. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992;152:523-8.